PHILADELPHIA--(BUSINESS WIRE)--Iroko Pharmaceuticals, LLC and iCeutica, Inc. announce Iroko’s acquisition of worldwide rights to two products formulated by iCeutica’s proprietary Encapsulated Organic Nanoparticle (EON™) Platform technology. In addition, Iroko and iCeutica will collaborate on the application of iCeutica’s EON Platform to reformulate an internal proprietary Iroko product. Iroko will guide progression of these EON formulated products through the regulatory process and ultimate launch.
